DURANEST Drug Patent Profile

When do Duranest patents expire, and what generic alternatives are available?

Duranest is a drug marketed by Astrazeneca and Dentsply Pharm and is included in two NDAs.

The generic ingredient in DURANEST is etidocaine hydrochloride. Additional details are available on the etidocaine hydrochloride profile page.

Summary for DURANEST

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	33
Patent Applications:	4,942
DailyMed Link:	DURANEST at DailyMed

US Patents and Regulatory Information for DURANEST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca	DURANEST	epinephrine; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-007	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Dentsply Pharm	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	021384-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for DURANEST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-005	Approved Prior to Jan 1, 1982	4,254,114
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-005	Approved Prior to Jan 1, 1982	3,862,321
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-005	Approved Prior to Jan 1, 1982	3,683,080
Astrazeneca	DURANEST	epinephrine; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-004	Approved Prior to Jan 1, 1982	3,812,147
Astrazeneca	DURANEST	etidocaine hydrochloride	INJECTABLE;INJECTION	017751-003	Approved Prior to Jan 1, 1982	3,862,321
Astrazeneca	DURANEST	epinephrine bitartrate; etidocaine hydrochloride	INJECTABLE;INJECTION	017751-007	Approved Prior to Jan 1, 1982	3,862,321

International Patents for DURANEST

See the table below for patents covering DURANEST around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	880963
Brazil	7108466
France	2118985
Japan	S5644063
Netherlands	7117644
Norway	135934

Market Dynamics and Financial Trajectory for Local Anesthesia Drugs: Focus on Duranest (Etidocaine)

Introduction

Local anesthesia drugs are a crucial component of modern medical practice, particularly in surgical and dental procedures. Among these, Duranest (etidocaine) is a significant player. This article delves into the market dynamics and financial trajectory of local anesthesia drugs, with a specific focus on Duranest.

Global Local Anesthesia Drugs Market Overview

The global local anesthesia drugs market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.6% from 2024 to 2030, reaching a market size of USD 5.14 billion by 2030[4].

Key Drivers of Market Growth

Several factors are driving the growth of the local anesthesia drugs market:

Increasing Surgical Procedures

The rise in surgical procedures, including cosmetic surgeries, dental procedures, and plastic surgeries, is a significant driver. Approximately 65% of total surgical procedures require post-operative pain management, which boosts the demand for local anesthesia drugs[4].

Aging Population

The growing geriatric population, who are more prone to chronic diseases and surgeries, is another key driver. By 2050, the proportion of the population above 60 years is expected to reach 22%, according to the World Health Organization[1].

Technological Advancements

Advancements in drug delivery systems, such as computer-based local anesthetic delivery and vibrotactile devices, are also contributing to market growth. For instance, Exparel, a local anesthetic formed by DepoFoam technology using bupivacaine liposome suspension, is an example of such innovation[1].

Regional Market Analysis

North America

North America dominates the local anesthesia drugs market, with a market share of 35.4% in 2023. This is attributed to the high prevalence of chronic diseases, a growing geriatric population, high per capita income, and improved access to healthcare in this region. The U.S. specifically holds a significant share of 29.4% due to the increase in aging population and the rise in surgical procedures[1].

Middle East and Africa (MEA)

The MEA region, although holding a low market share, is anticipated to witness significant growth due to growing public awareness and demographic shifts such as urbanization and lifestyle changes. The rise in chronic diseases in this region is also expected to drive the demand for local anesthesia drugs[1].

Duranest (Etidocaine) Market Dynamics

Product Overview

Duranest, also known as etidocaine, is a long-acting local anesthetic used in various medical procedures. It is known for its potent and long-lasting effects, making it a preferred choice for surgeries requiring extended pain relief.

Market Position

While the market is dominated by injectables, which accounted for 59.5% of the market revenue in 2023, Duranest falls under this category. Its long-acting nature aligns with the increasing demand for effective post-operative pain management[1].

Competitive Landscape

The local anesthesia drugs market is competitive, with key players such as Johnson & Johnson Services Inc, Pfizer Inc., AstraZeneca plc, and Novartis AG. These companies are expanding their market share through new product launches, collaborations, and other strategic initiatives. Duranest, being a part of this competitive landscape, must continually innovate and improve to maintain its market position[1].

Financial Trajectory

Revenue Growth

The global local anesthesia drugs market, including Duranest, is expected to grow steadily. With a projected CAGR of 3.6%, the market is anticipated to reach USD 5.14 billion by 2030. This growth is driven by the increasing demand for effective pain management solutions in surgical procedures[4].

Market Segments

The market is segmented by drug type, application, and region. Duranest, as a long-acting injectable anesthetic, benefits from the growing demand for injectable local anesthetics, which accounted for the largest market revenue share in 2023[1].

Regional Performance

In regions like North America, where the market is more mature, Duranest is likely to see stable growth. In emerging markets such as the MEA region, there is potential for significant growth driven by increasing public awareness and the rise in chronic diseases[1].

Technological and Regulatory Trends

Advanced Drug Delivery Systems

The development of advanced drug delivery systems, such as DepoFoam technology, is expected to boost the market for local anesthesia drugs. These innovations enhance the efficacy and duration of action of local anesthetics like Duranest[1].

Regulatory Environment

Government initiatives and regulatory support for the development of pharmaceutical drug delivery systems are crucial for market growth. In regions like North America, these initiatives are expected to drive the adoption of advanced local anesthesia drugs, including Duranest[3].

Challenges and Opportunities

Increasing Health Care Spending

The rise in health care spending and government funding for drug-delivery research are positive factors for the market. However, the pressure to reduce pharmaceutical prices, especially in emerging economies, poses a challenge to the profitability of pharmaceutical companies[3].

Growing Demand in Emerging Markets

The increasing incidence of chronic illnesses in developing economies presents a significant opportunity for local anesthesia drugs like Duranest. The growing senior population in countries like Japan also drives the demand for these drugs[3].

Key Takeaways

• The global local anesthesia drugs market is projected to grow at a CAGR of 3.6% from 2024 to 2030.
• Duranest, as a long-acting injectable anesthetic, benefits from the growing demand for effective post-operative pain management.
• North America dominates the market, but emerging regions like MEA offer significant growth opportunities.
• Technological advancements in drug delivery systems and regulatory support are key drivers of market growth.
• Challenges include pressure to reduce pharmaceutical prices and the need for continuous innovation.

FAQs

What is the projected market size of the global local anesthesia drugs market by 2030?

The global local anesthesia drugs market is anticipated to reach USD 5.14 billion by 2030[4].

Which region dominates the local anesthesia drugs market?

North America dominates the local anesthesia drugs market, with a market share of 35.4% in 2023[1].

What are the key drivers of the local anesthesia drugs market?

Key drivers include the increasing number of surgical procedures, the growing geriatric population, and technological advancements in drug delivery systems[1][4].

How does Duranest fit into the market for local anesthesia drugs?

Duranest is a long-acting injectable anesthetic, benefiting from the growing demand for effective post-operative pain management and the dominance of injectables in the market[1].

What are the challenges faced by the local anesthesia drugs market?

Challenges include the pressure to reduce pharmaceutical prices, especially in emerging economies, and the need for continuous innovation to maintain market position[3].

Sources

1. Grand View Research: Local Anesthesia Drugs Market Size & Share Report, 2030.
2. Marshall USC: Implied Equity Duration: A Measure of Pandemic Shutdown Risk.
3. Maximize Market Research: Pharmaceutical Drug Delivery Market: Industry Analysis.
4. GlobeNewswire: Local Anesthesia Drugs Market Size, Share & Trends Analysis Report 2024-2030.